

# Chapter 233

## Immunosuppressive and Immunomodulatory Drugs

Jeffrey P. Callen

### REFERENCES

1. Madan V, Griffiths CE: Systemic ciclosporin and tacrolimus in dermatology. *Dermatol Therapy* **20**: 237-250, 2004
2. Kahan BD, Kramer WG: Median effect analysis of efficacy versus adverse effects of immunosuppressants. *Clin Pharmacol Ther* **70**:74, 2001
3. Kalajian AH, Van Meter JR, Callen JP: Sarcoïdal anemia and leukopenia treated with methotrexate and mycophenolate mofetil. *Arch Dermatol* **145**(8):905-909, 2009
4. Vicari-Christensen M, Reppers S, Basile S, Young D: Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. *Prog Transplant* **19**(3):277-284, 2009
5. Kovarik JM, Mueller EA, Richard F, Niese D, Hal-loran PF, Jeffery J, Paul LC, Keown PA: Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. *Transplantation* **62**(6):759-763, 1996
6. Lee CS, Koo JYM: Cyclosporin. In: *Comprehensive Dermatologic Drug Therapy*, 2nd edition, edited by SE Wolverton. Philadelphia, Elsevier, 2007, pp. 219-237
7. Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG: Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. *Transplantation* **62**:123-125, 1996
8. Dubertret L: Retinoids, methotrexate and cyclosporine. *Curr Probl Dermatol* **38**:79-94, 2009
9. Matis WL, Ellis CN, Griffiths CE, Lazarus GS: Treatment of pyoderma gangrenosum with cyclosporine. *Arch Dermatol* **128**(8):1060-1064, 1992
10. Gelbard CM, Hebert AA: New and emerging trends in the treatment of atopic dermatitis. *Patient Prefer Adherence* **2**:387-392, 2008
11. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, Valente J: Behçet's disease—a contemporary review. *J Autoimmun* **32**(3-4):178-188, 2009
12. Kim BJ, Min SU, Park KY, Choi JW, Park SW, Youn SW, Park KC, Huh CH: Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. *J Dermatolog Treat* **19**(4):216-220, 2008
13. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, Weinstein G: Cyclosporine consensus conference with emphasis on the treatment of psoriasis. *J Am Acad Dermatol* **39**:464-475, 1998
14. Binet I, Wallnöfer A, Weber C, Jones R, Thiel G: Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine. *Kidney Int* **57**:224, 2000
15. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS: Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. *Transplantation* **68**(10):1517-1525, 1999
16. Kirchner GI, Meier-Wiedenbach I, Manns MP: Clinical pharmacokinetics of everolimus. *Clin Pharmacokinet* **43**:83-95, 2004
17. Kaplan MJ, Ellis CN, Bata-Csorgo Z, Kaplan RS, Endres JL, Fox DA: Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: Association of capillary leak syndrome with apoptosis of lesional lymphocytes. *Arch Dermatol* **135**:553-557, 1999
18. Edge JC, Outland JD, Dempsey JR, Callen JP: Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. *Arch Dermatol* **142**(1):65-69, 2006
19. Eaton PA, Callen JP: Mycophenolate mofetil as therapy for pyoderma gangrenosum. *Arch Dermatol* **145**(7):781-785, 2009
20. Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T: Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. *Br J Dermatol* **156**(6):1321-1327, 2007

21. Cho BK, Sah D, Chwalek J, Roseborough I, Ochoa B, Chiang C, Price VH: Efficacy and safety of mycophenolate mofetil for lichen planopilaris. *J Am Acad Dermatol* **62**(3):393-397, 2010
22. Nousari HC, Lynch W, Anhalt GJ, Petri M: The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. *Arch Dermatol* **134**:1509-1511, 1998
23. Nousari HC, Griffin WA, Anhalt GJ: Successful therapy for bullous pemphigoid with mycophenolate mofetil. *J Am Acad Dermatol* **39**:497-498, 1998
24. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC: Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. *Arch Dermatol* **139**(6):739-742, 2003
25. Waldman MA, Callen JP: Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. *J Am Acad Dermatol* **51**(2 Suppl):S124-S130, 2004
26. Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN: Mycophenolate mofetil in dermatomyositis: is it safe? *Neurology* **66**(8):1245-1247, 2006